Raymond James Financial Services Advisors Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 978,408 shares of the company’s stock after selling 14,626 shares during the quarter. Johnson & Johnson accounts for 0.8% of Raymond James Financial Services Advisors Inc.’s portfolio, making the stock its 14th biggest position. Raymond James Financial Services Advisors Inc.’s holdings in Johnson & Johnson were worth $127,208,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after acquiring an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Johnson & Johnson by 47.9% during the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after buying an additional 2,581,562 shares during the last quarter. Finally, Harbour Capital Advisors LLC boosted its position in shares of Johnson & Johnson by 13,327.8% during the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after buying an additional 2,482,843 shares during the last quarter. Hedge funds and other institutional investors own 65.71% of the company’s stock.
Johnson & Johnson (JNJ) opened at $146.86 on Wednesday. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $148.06. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $394,540.00, a P/E ratio of 25.50, a PEG ratio of 2.75 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $1.68 EPS. research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.29%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Several equities research analysts recently commented on JNJ shares. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a research report on Thursday, October 19th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.40 price objective on the stock in a research report on Monday, January 1st. Royal Bank of Canada increased their target price on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Citigroup initiated coverage on Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 target price on the stock. Finally, Goldman Sachs Group downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their target price for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $145.94.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/17/johnson-johnson-jnj-stake-lessened-by-raymond-james-financial-services-advisors-inc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.